If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
101
results.
Updated on
20/08/2026 [07:51:00]
Absstract of: US20260234726A1
This invention relates to a biomarker combination, diagnostic kits and methods for diagnosis of dilated cardiomyopathy, and use of the biomarker combination in preparation of the diagnostic kits for dilated cardiomyopathy. The biomarker combination comprises miR-126-5p and a tyrosine phosphorylation level of PECAM-1 proteins, wherein an expression level of miR-126-5p is upregulated in patients with dilated cardiomyopathy, and the tyrosine phosphorylation level of PECAM-1 protein is increased in the patients with the dilated cardiomyopathy.
Absstract of: US20260235604A1
The present invention relates to the Asparagine Synthetase (Asns) gene and the role it plays in cardiomyocyte dedifferentiation and cardiac regeneration. More particularly, the invention is directed to the detection of ASNS expression as a diagnostic marker for cardiomyocyte dedifferentiation and cardiac regeneration; therapeutic up- and downregulation of ASNS expression to augment dedifferentiation-regeneration or suppress dedifferentiation-regeneration; and methods of screening for ASNS inhibitors, activators and regulators of cardiomyocyte dedifferentiation activity. Also disclosed are vectors, probes, therapeutics and kits.
Absstract of: WO2026167636A2
The present invention provides methods, systems, platforms, kits and computer- implemented processes for predicting, diagnosing, classifying, profiling diabetes, prediabetes (or intermediate hyperglycemia) and diabetes-related cardiometabolic disorders and complications in a subject, and for performing precision treatment selection and clinical decision-making. In some embodiments, the invention comprises individual modules, wherein each module generates outputs comprising one or more of disease risk stratification, subtype classification, complication risk prediction, pharmacogenomic predictions, and treatment recommendations. In certain embodiments, the invention further provides an integrated, multi-method, multi-functional system, platform, kit or computer-implemented method wherein two or more of the individual modules are integrated to generate individualized health data for personalized management, selection for participation in clinical trials and generation of real-world evidence to complement clinical trial evidence for evaluation of safety, tolerability, clinical effectiveness and cost-effectiveness of interventions. Other example embodiments are described herein.
Absstract of: WO2026170058A1
Methods, kits, and computer-implemented systems are provided for diagnosing, predicting, or treating atherosclerosis or progression thereof in a subject.
Absstract of: US20260224660A1
The cardiac diastolic function-improving agent according to an embodiment of the present invention comprises a polynucleotide encoding a reprogramming factor polypeptide Gata4.
Absstract of: WO2026163010A2
A method of assessing expression profiles of miRNA markers using predictive classification models to distinguish between non-diseased and diseased mitral valve disease, non-diseased and diseased DCM, non-diseased and diseased HCM. Additionally, an assessment of the same method is provided to discriminate pre-clinical from clinical MMVD or DCM patients. Also provided is a method of differentially diagnosing MMVD patients from DCM patients or from healthy controls.
Absstract of: AU2025213424A1
The present invention relates to the field of disease treatment, and particularly to use of a reagent capable of inhibiting or knocking out Jun gene expression in the treatment of heart failure with preserved ejection fraction (HFpEF) and a method for drug screening.
Absstract of: WO2026164500A1
The present invention relates to a novel biomarker for the diagnosis of uremic cardiomyopathy and use thereof. By discovering the novel biomarker for the diagnosis of uremic cardiomyopathy, uremic cardiomyopathy can be diagnosed early and an appropriate treatment method can be provided, which may contribute to improving patient prognosis, reducing medical costs, and the like.
Absstract of: US20260207775A1
The invention relates to the field of diseases caused by high levels of LDL-C and/or fibrinogen, such as cardiovascular disease. The invention involves oligonucleotides for RNA editing technology in deaminating target adenosine nucleotides, such as the adenosine at position 1055, in transcripts of the human B4GALT1 gene.
Absstract of: US20260209290A1
Disclosed is a method, a pharmaceutical composition, and a pharmaceutical preparation for prevention and/or treatment of pulmonary arterial hypertension (PAH). The method includes administering to a subject at least one of a first agent that inhibits binding of Hic-5 to SMAD7 or a second agent that inhibits Hic-5.
Absstract of: WO2026156121A1
The present disclosure relates generally to the treatment of subjects having a lipid disorder or a cardiovascular disease or at risk of developing a lipid disorder or a cardiovascular disease by administering a Phospholipase A2 Group XIIB (PLA2G12B) inhibitor to the subject.
Absstract of: US20260210975A1
0000 A method of determining a risk of developing a neurological disorder in a Long-COVID patient comprising: (a) testing levels of at least one marker associated with a neurologic disorder in a sample taken from the Long-COVID patient, and (b) making a determination that the Long-COVID patient is at risk of developing said neurological disorder when the levels of said at least one marker is increased in the Long-COVID patient compared to healthy control reference levels of said marker. Also a method of determining a risk of developing a cardiometabolic injury in a Long-COVID patient when the levels of expression of a marker associated to a cardiometabolic injury is different in the Long-COVID patient than the levels of said marker in a healthy control. Also methods of treating Long-COVID with a drug effective to mediate the HIF signaling pathway.
Absstract of: US20260201372A1
0000 Compositions and methods are disclosed for treating metabolic syndrome-associated heart disease cardiomyopathy and/or heart failure, wherein the method comprises the step of increasing the concentration of LIPTER RNA in the cardiomyocytes of said patient.
Absstract of: US20260201474A1
0000 The present disclosure relates generally to methods for accurately predicting the risk of cancer-associated venous thromboembolism (CAT) and/or preventing CAT in cancer patients using ctDNA as a biomarker.
Absstract of: WO2026148565A1
The use of annexin A2 (ANXA2) and an inhibitor thereof in the diagnosis, treatment and/or prevention of pulmonary hypertension. Specifically disclosed is the use of an ANXA2 inhibitor (comprising an siRNA for silencing the ANXA2 gene, an ANXA2 antibody, and a phosphorylation inhibitor) in the preparation of a product for preventing and/or treating pulmonary hypertension. It is verified in experiments that the ANXA2 inhibitor can significantly inhibit the proliferation and migration of pulmonary arterial smooth muscle cells, and significantly ameliorate pulmonary hypertension, pulmonary arterial vascular remodeling, and right ventricular hypertrophy. The ANXA2 or ANXA2 protein Thr208 phosphorylation site can be used in the diagnosis or assisted diagnosis of pulmonary hypertension, or in the screening of drugs for pulmonary hypertension and the development of new diagnostic and therapeutic methods and drugs. The developed therapeutic target and ANXA2 inhibitor have a high clinical application value in the fields of diagnosis, prevention, and treatment of pulmonary hypertension.
Absstract of: WO2026152007A1
Disclosed are methods for assessing the likelihood of a subject developing coronary artery disease (CAD). The methods comprise determining a polygenic risk score based on a set of single nucleotide polymorphisms associated with endothelial cell function. The assessment may include the subject's LDL-C levels as a factor, and the methods include determining a subject's sensitivity to LDL-C mediated CAD. Determination of increased risk for CAD is followed by treatment with an anti-CAD therapy.
Absstract of: WO2026149323A1
Provided are the methods of use and pharmaceutical compositions of mitochondrial uncouplers and glucagon-like peptide-1 receptor agonists for treating various diseases and conditions, including obesity, T2DM, liver diseases and conditions (e.g., MASH), and cardiovascular diseases and conditions(e.g.,heart failure).
Absstract of: US20260191897A1
0000 The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
Absstract of: US20260193711A1
0000 Method of prediction of pregnancy complications associated with a high risk of pregnancy loss, such as miscarriage, stillbirth, or HELLP syndrome. Pregnant women are screened to determine the expression profile of two or more miRNAs in whole peripheral venous blood collected in the period of 10th-13th gestational week, whereas said two or more miRNAs are selected from the group miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-26a-5p, miR-130b-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-342-3p, miR-499a-5p a miR-574-3p.
Absstract of: WO2025046293A1
A method of assessing expression profiles of miRNA markers using predictive classification models to differentially diagnosing MMVD patients from healthy controls or DCM patients from healthy controls. Additionally, an assessment of the same method to discriminate pre-clinical from clinical MMVD or DCM patients. Also provided is a method of differentially diagnosing MMVD patients from DCM patients or from healthy controls.
Absstract of: CN122326737A
The invention belongs to the field of biomedical engineering, and relates to an application of SnoRNA Gm26330 as a myocardial hypertrophy biomarker and a therapeutic target. The invention provides a marker snoRNA (ribonucleic acid) Gm26330 related to myocardial hypertrophy, wherein the nucleotide sequence of the snoRNA Gm26330 is as shown in SEQ ID No. 1. The invention also provides a kit for detecting myocardial hypertrophy. In-vivo and in-vitro experiments show that the SnoRNA Gm26330 can inhibit the cardiac hypertrophy, the SnoRNA Gm26330 has a protection effect on myocardial damage caused by the cardiac hypertrophy, and the SnoRNA Gm26330 has a potential value for preparing the medicine for preventing and treating the related heart diseases.
Absstract of: CN122314366A
The invention relates to a group of genes related to gestational hypertension, a method for predicting gestational hypertension in early pregnancy by using the related genes and related application thereof. Specifically, a transcript starting site characteristic value of at least one of LOC124902572, EEF1A1P16, LOC105369767, GOLM2, CDRT7, MEIS3 and LOC105376108 in a to-be-detected pregnant woman cfDNA sample is obtained, and after the transcript starting site characteristic value is input into a prediction model, whether the risk of gestational hypertension exists or not is judged according to an output result. The initial site feature value of the transcript is the sequence number of the corrected transcriptional initial site region. The obtained prediction model can effectively and stably perform early prediction on the risk of gestational hypertension (including preeclampsia) in the early pregnancy so as to assist a doctor in performing early pregnancy intervention on a subject and reduce the occurrence risk of gestational hypertension.
Absstract of: CN122303422A
The invention relates to the field of biological medicine, and discloses a biomarker composition based on mitochondrial oxidative stress for auxiliary diagnosis of dilated cardiomyopathy and application of the biomarker composition. The biomarker combination comprises a TARS2 gene, a NOX4 gene and an SNCA gene. The biomarker combination can be applied to preparation of an auxiliary diagnosis kit for dilated cardiomyopathy, auxiliary diagnosis of dilated cardiomyopathy can be efficiently and accurately achieved by detecting the expression level of each gene in the biomarker combination, and compared with a traditional diagnosis means, the biomarker combination has the advantages that the sensitivity is high on the basis of mitochondrial oxidative stress related gene characteristics, and the sensitivity is high. The diagnosis accuracy is higher, and the applicability is better.
Absstract of: CN122297507A
The invention discloses an application of circFBXW4 in preparation of a medicine for treating cerebral apoplexy. The circFBXW4 inhibits FUS aggregation after cerebral arterial thrombosis and increases the free form of FUS by combining and adsorbing FUS, so that expression of downstream target protein HECTD1 and a ubiquitination substrate IQGAP1 of the downstream target protein HECTD1 is up-regulated, and then activation of astrocytes is inhibited. According to the application disclosed by the invention, the action mechanism of circFBXW4 in cerebral apoplexy diseases is systematically elaborated for the first time, and circFBXW4 is expected to become a novel biomarker and a molecular treatment target for clinically treating acute ischemic cerebral apoplexy.
Nº publicación: CN122303424A 30/06/2026
Applicant:
AEROSPACE CENTER HOSPITAL
\u822A\u5929\u4E2D\u5FC3\u533B\u9662
Absstract of: CN122303424A
The invention discloses application of GGCX in preparation of a reagent for diagnosis or auxiliary diagnosis of cerebral arterial thrombosis. Firstly, by constructing a six-layer progressive genetics evidence system, it is proved that gamma-glutamyl carboxylase (GGCX) is up-regulated to the protection direction of cerebral arterial thrombosis, and the protection effect has subtype specificity. Secondly, constructing a diagnosis model based on peripheral blood GGCX expression data; and finally, verifying that the GGCX is obviously reduced under the ischemia condition through three aspects of clinical sample qPCR (quantitative polymerase chain reaction) detection, a tMCAO/R animal model and a primary hippocampal neuron OGD/R cell model, and clinically verifying that the AUC value of a queue is 0.889. The invention provides a reliable scheme based on the peripheral blood biomarker GGCX for early auxiliary diagnosis of cerebral arterial thrombosis. And the kit has definite clinical value and important significance for improving the early diagnosis rate of cerebral arterial thrombosis and shortening the time from morbidity to treatment.
BOPI
Electronic site
